Heartwire reported on 24th May, 2011 that the use of the combination therapy azilsartan medoxomil (Edarbi, Takeda Pharmaceuticals) and chlorthalidone resulted in a more effective reduction in systolic blood pressure (SBP), including ambulatory measures of blood pressure, when compared with combination therapy of olmesartan (Benicar, Daiichi Sankyo) and hydrochlorothiazide (HCTZ) in patients with hypertension, according to the results of a new study.
Presenting the data this week during the late-breaking clinical trials session at the American Society of Hypertension (ASH) 2011 Scientific Meeting, lead investigator Dr William Cushman (Veterans Affairs Medical Center, Memphis, TN) noted that azilsartan, a new angiotensin-receptor blocker (ARB) approved by FDA in February this year, is a highly effective, long-acting agent that is currently in development as a fixed-dose combination with chlorthalidone, a thiazidelike diuretic.
Speaking with the media during a press conference announcing the results, Cushman said chlorthalidone was selected as the second agent with azilsartan and partnered in development because there is growing evidence the drug is more effective than HCTZ. The purpose of the study was to compare the effectiveness of the azilsartan/chlorthalidone combination with the maximum approved dose of olmesartan/HCTZ, that being 40/25 mg.
No comments:
Post a Comment